Page last updated: 2024-12-05

rimantadine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rimantadine is an antiviral medication used to treat and prevent influenza A infections. It inhibits the replication of the influenza virus by blocking the M2 ion channel, which is essential for the virus's entry into the host cell. Rimantadine is typically prescribed for the treatment of influenza A infections in adults and children over the age of 1 year. It is also used for the prevention of influenza A infections in people who are at high risk of complications from the virus. Rimantadine is available as an oral tablet and is generally well-tolerated. Common side effects include nausea, vomiting, headache, and dizziness. Rimantadine is generally not recommended for use in pregnant women or breastfeeding mothers. Rimantadine is a synthetic compound that was first developed in the 1960s. It is effective against a variety of influenza A viruses, including those that are resistant to other antiviral drugs. Rimantadine is a valuable tool for the prevention and treatment of influenza A infections. Its ability to block the M2 ion channel is a key factor in its antiviral activity. However, the development of influenza viruses that are resistant to rimantadine has limited its use in some cases. Research is ongoing to develop new antiviral drugs that are effective against influenza viruses, including those that are resistant to rimantadine. The importance of rimantadine lies in its ability to reduce the severity and duration of influenza A infections. It is also an important tool for the prevention of influenza A infections in people who are at high risk of complications from the virus. Research into rimantadine is ongoing, and it is likely that new uses for this compound will be discovered in the future.'

Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5071
CHEMBL ID959
CHEMBL ID1201272
CHEBI ID94440
SCHEMBL ID2981
SCHEMBL ID2619249
SCHEMBL ID20409367
MeSH IDM0019119

Synonyms (97)

Synonym
rimantadinum [inn-latin]
1-(1-adamantyl)ethylamin
1-adamantanemethylamine, alpha-methyl-
riamantadine
tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, alpha-methyl-
rimantadina [inn-spanish]
tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl-
hsdb 7438
brn 2715740
rimantadine [inn:ban]
AB00959689-03
rimantidine & .alpha.ifn
rimant & .alpha. ifn
tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl- & ifn.alpha
ENAMINE_005755 ,
1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine
1-adamantanemethylamine, .alpha.-methyl-
.alpha.-methyladamantanemethylamine
IDI1_007990
OPREA1_602732
13392-28-4
rimantadine
C07236
1-(1-adamantyl)ethanamine
tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-
rimant
alpha-methyl-1-adamantanemethylamine
NCGC00159491-03
alpha-methyladamantanemethylamine
DB00478
STK177253
1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine
MAYBRIDGE1_002066
HMS2090L19
AKOS000264537
CHEMBL959 ,
rimantadin
HMS1410F13
D08483
rimantadine (inn)
1-(adamantan-1-yl)ethan-1-amine
1-(1-adamantyl)ethylamine
1-adamantan-1-yl-ethylamine
1-adamantan-1-ylethylamine
1-(1-adamantyl)-ethylamine
rimantadinum
rimantadina
unii-0t2ef4jqtu
0t2ef4jqtu ,
CHEMBL1201272
BBL013215
AKOS006238592
FT-0630403
NCGC00159491-05
AM84461
AB00638368-09
S1964
BRD-A84282119-003-01-2
bdbm50216627
rimantidin
(alpha-methyl-1-adamantyl)methylamine
rimantadine [who-dd]
rimantadine [hsdb]
(rs)-1-(1-adamantyl)ethanamine
rimantadine [vandf]
rimantadine [inn]
rimantadine [mi]
HY-B0338
AKOS016038537
SCHEMBL2981
SCHEMBL2619249
tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, .alpha.-methyl-
tricyclo[3,3,1,1(3,7)]decane-1-methanamine, .alpha.-methyl-
.alpha.-methyl-1-adamantanemethylamine
HMS3604N13
AB01506092_03
AB01506092_02
SCHEMBL20409367
DTXSID2023561 ,
CCG-236078
CHEBI:94440
HMS3655J05
1-rimantadine
AS-68744
rimantadin a
SBI-0206810.P001
SW220023-1
BCP12269
Q42171
EN300-33990
2-methyl-5-nitrobenzenesulfonic acid-[1-(1-adamantyl)ethyl]amine (1:1)
4-bromo-7-(trifluoromethyl)- quinoline
NCGC00159491-11
tricyclo[3.3.1.13,7]decane-1-methanamine, a-methyl-
dtxcid503561
rimantadinum (inn-latin)
rimantadina (inn-spanish)

Research Excerpts

Overview

Rimantadine is a synthetic antiviral agent used in prophylaxis and in treating the early stages of uncomplicated influenza A illness.

ExcerptReferenceRelevance
"Rimantadine is a synthetic antiviral agent used in prophylaxis and in treating the early stages of uncomplicated influenza A illness. "( Measurement of rimantadine in plasma by capillary gas chromatography/mass spectrometry with a deuterium-labeled internal standard.
Anonick, PK; Hayden, FG; Herold, DA; Kinter, M, 1988
)
2.07

Effects

Rimantadine has no significant antiviral activity against HCV. It has been shown to be more active in vitro and less toxic than amantadines in adults with influenza A disease.

ExcerptReferenceRelevance
"Rimantadine has no significant antiviral activity against HCV."( A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy.
Clarke-Platt, J; Fong, TL; Fried, MW, 1999
)
2.09
"Rimantadine has thus far remained unlicensed, and attention has become focused on antiviral resistance to these drugs, an issue previously recognized but not considered important in decisions concerning drug use."( Implications of viral resistance to amantadine in control of influenza A.
Arden, NH; Monto, AS, 1992
)
1
"Rimantadine has been shown to be more active in vitro and less toxic than amantadine in adults with influenza A disease. "( Serum concentrations and safety of rimantadine in paediatric patients.
Brady, MT; Nahata, MC, 1986
)
1.99

Treatment

Oral rimantadine treatment did not reduce the otologic manifestations of experimental influenza in adults or natural influenza in children. Rimantdine treatment failed to restore growth or pituitary GH contents.

ExcerptReferenceRelevance
"Rimantadine treatment failed to restore growth or pituitary GH contents."( Hypothalamic growth hormone-releasing hormone (GHRH) deficiency: targeted ablation of GHRH neurons in mice using a viral ion channel transgene.
Carmignac, DF; Houston, P; Le Tissier, PR; Lilley, S; Magoulas, C; Mathers, K; Ogden, D; Phelps, CJ; Robinson, IC; Sesay, AK, 2005
)
1.05
"Rimantadine treatment is no longer recommended."( Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltamivir treatment of symptomatic cases.
Drinka, PJ; Haupt, T, 2007
)
1.43
"Oral rimantadine treatment did not reduce the otologic manifestations of experimental influenza in adults or natural influenza in children."( Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention.
Hayden, FG, 2000
)
0.76
"Treatment with rimantadine of influenza in children and the potential development of resistance in clinical isolates associated with therapy have not been previously studied. "( Children with influenza A infection: treatment with rimantadine.
Disney, FA; Dolin, R; Francis, AB; Gala, CL; Green, JL; Hall, CB; Madore, PH; Markovitz, DM; Talpey, WB; Zhang, YQ, 1987
)
0.88

Toxicity

Amantadine use was associated with a significantly higher incidence of central nervous system adverse events than rimantadne use in this elderly population receiving influenza prophylaxis. There are no data examining the rate of adverse reactions in elderly patients who receive amantadistine vs rimantsadine.

ExcerptReferenceRelevance
" Subjects were monitored for adverse effects and evidence of influenza virus infection weekly for six weeks."( Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic.
Brady, MT; Clements, ML; DePamphilis, J; Oakes, M; Pacini, DL; Samorodin, R; Sears, SD; Soo, W, 1990
)
0.54
"Rimantadine has been shown to be more active in vitro and less toxic than amantadine in adults with influenza A disease."( Serum concentrations and safety of rimantadine in paediatric patients.
Brady, MT; Nahata, MC, 1986
)
1.99
" The plasma drug concentrations after the first dose correlated significantly with total symptom sources for both amantadine and rimantadine, but the plasma levels of toxic and nontoxic subjects overlapped extensively."( Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.
Hayden, FG; Hoffman, HE; Spyker, DA, 1983
)
0.71
" Their adverse effects mostly involve bone marrow depression (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" While data suggest that rimantadine is better tolerated, there are no data examining the rate of adverse reactions in elderly patients who receive amantadine vs rimantadine."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.84
" Patients were assessed for central nervous system adverse effects and therapy discontinuation occurring with each agent."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.54
"6%) of the 156 patients experienced an adverse effect when receiving amantadine compared with 3 patients (1."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.54
"Amantadine use was associated with a significantly higher incidence of central nervous system adverse events than rimantadine use in this elderly population receiving influenza prophylaxis."( Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000
)
0.75
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" To assess potential neurologic adverse effects of oseltamivir use in infants, a retrospective chart review was performed in infants less than 12 months of age who received oseltamivir, amantadine, or rimantadine."( Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.
Abughali, N; Abzug, MJ; Bradley, JS; Cloud, GA; Englund, J; Griffin, J; Guzman-Cottrill, J; Jacobs, RF; Jester, P; Kimberlin, DW; Lang, D; Leach, C; Ramilo, O; Robinson, J; Romero, JR; Shalabi, M; Shelton, M; Storch, G; Wade, KC; Whitley, RJ, 2010
)
0.55
"The primary objective was to describe the frequency of neurologic adverse events among children less than 12 months of age who received oseltamivir compared with those receiving adamantanes."( Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.
Abughali, N; Abzug, MJ; Bradley, JS; Cloud, GA; Englund, J; Griffin, J; Guzman-Cottrill, J; Jacobs, RF; Jester, P; Kimberlin, DW; Lang, D; Leach, C; Ramilo, O; Robinson, J; Romero, JR; Shalabi, M; Shelton, M; Storch, G; Wade, KC; Whitley, RJ, 2010
)
0.36
" There were no serious adverse events and no deaths."( Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study.
Ballester-Sanchis, RM; Brennan, BJ; Cirrincione-Dall, G; Davies, BE; Navarro, MT, 2012
)
0.62

Pharmacokinetics

The half-life of rimantadine in young adults was 27. The developed assay method was successfully applied to a pharmacokinetic study in rats.

ExcerptReferenceRelevance
" No differences were observed among the age-stratified groups in measured or derived pharmacokinetic parameters."( Multiple-dose pharmacokinetics of rimantadine in elderly adults.
Gustavson, LE; Hayden, FG; Tominack, RL; Wills, RJ, 1988
)
0.55
" The plasma half-life (43."( Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure.
Capparelli, EV; Chow, MS; Izard, M; Stevens, RC; Wills, RJ, 1988
)
1.72
" The half-life of rimantadine in young adults was 27."( Pharmacokinetics of a single dose of rimantadine in young adults and children.
Anderson, EL; Bartram, J; Belshe, RB; Hoffman, HE; Van Voris, LP, 1987
)
0.88
"22 micrograms/ml), plasma elimination half-life (36."( Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults.
Hayden, FG; Hoffman, HE; Minocha, A; Spyker, DA, 1985
)
0.5
" On the other hand, pharmacokinetic parameters of AMA did not significantly change."( Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies.
Fujii, Y; Higashi, Y; Uemori, I, 2005
)
0.59
" The developed assay method was successfully applied to a pharmacokinetic study in rats after oral administration of rimantadine hydrochloride at the dose of 20 mg/kg."( Determination of rimantadine in rat plasma by liquid chromatography/electrospray mass spectrometry and its application in a pharmacokinetic study.
Chen, L; Chen, M; Gong, L; Jiang, M; Ju, W; Tan, H; Xia, X; Xiong, N; Xu, M; Zhang, J, 2008
)
0.89
" The pharmacokinetic parameters and bioavailability of TZV were calculated after the administration of TZV to rabbits."( Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
Charushin, V; Chupakhin, O; Deev, S; Deeva, E; Ivanov, A; Karpenko, I; Kiselev, O; Kochetkov, S; Kukhanova, M; Rusinov, V; Smirnova, O; Ulomsky, E; Yanvarev, D, 2010
)
0.36
" The pharmacokinetic parameters of allindicated active components exhibited no detectable distinctions, except for the time to attaining maximum concentration ofparacetamol and the value of the maximum concentration of loratadine."( [Comparative pharmacokinetics of antigrippin-maximum administered in capsules and powder for preparing solutions].
Belolipetskaia, VG; Belolipetskiĭ, NA; Blagodatskikh, SV; Guranda, DF; Kibalchich, DA; Rudenko, LI; Zhabina, EA, 2011
)
0.37
" Two studies were conducted to assess the potential for pharmacokinetic interactions of peramivir when coadministered with oseltamivir or rimantadine."( Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.
Atiee, G; Baughman, S; Collis, P; Hernandez, J; Hollister, A; Lasseter, K; McCullough, A, 2012
)
0.8
" Elimination half-life was unaffected by coadministration."( Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study.
Ballester-Sanchis, RM; Brennan, BJ; Cirrincione-Dall, G; Davies, BE; Navarro, MT, 2012
)
0.62
" pharmacokinetic profile of a drug is unchanged in the presence of CD."( The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds.
Leong, NJ; Mcintosh, MP; Prankerd, RJ; Shackleford, DM, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" Inoculation of remantadine in combination with nontoxic concentrations of sodium selenite was found to be a promising combination for inhibition of experimental influenza infection."( [Antiviral action of sodium selenite and its combination with remantadine].
Abdullaev, FI; Abdullaev, II; Lazymova, ZA; Sycheva, IV; Veselovskaia, TV,
)
0.13
" They must be administered with caution during pregnancy, because some are known teratogens (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
"It was shown advisable to use ribavirin (a weak inhibitor of Sindbis virus reproduction) in combination with ACAA."( [Effect of the amide of 1-adamantanecarboxylic acid (AACA) and its combination with ribavirin on the course of experimental infection, caused by the sindbis virus in tissue culture and in mouse brain. Possible isolation of the virus mutant resistant to ri
Andronova, VL, 1997
)
0.3
" A variety of drugs have been investigated alone or in combination with alpha interferons."( The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
Perrillo, RP; Younossi, ZM, 1999
)
0.61
" The use of every of the compounds in combination with rimantadine resulted in a 2-16 times decrease of their EC50 and correction of the concentration-effect relation of rimantadine."( [New betulin derivatives in combination with rimantadine for inhibition of influenza virus reproduction].
Boreko, EI; Pavlova, NI; Savinova, OV, 2009
)
0.86

Bioavailability

The main objective was to modify therapy with adamantane derivatives. Saccharomyces cerevisiae was the model organism. There were no changes in the rate of absorption and the renal clearance of rimantadine when it was administered with cimetidine.

ExcerptReferenceRelevance
" There were no changes in the rate of absorption and the renal clearance of rimantadine when it was administered with cimetidine."( Effect of cimetidine on the disposition of rimantadine in healthy subjects.
Brown, SY; Choma, N; Holazo, AA; Lee, LF; Wills, RJ, 1989
)
0.77
" The bioavailability after an oral dose of 40 mg/kg was 58."( Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs.
Blasecki, JW; Gaylord, JC; Hoffman, HE; Shalaby, LM; Whitney, CC, 1988
)
0.55
"Twenty healthy male subjects completed an open-label randomized crossover design to assess the bioavailability of 100 mg of rimantadine HCl in tablet and syrup forms relative to an oral solution."( Relative bioavailability of rimantadine HCl tablet and syrup formulations in healthy subjects.
Buonpane, G; Choma, N; Keigher, N; Lin, A; Wills, RJ, 1987
)
0.77
" It is obvious that most important problem in clinical use of anti-FluV drugs should be its side effects, bioavailability and stability in human bodies."( [Current status of research and development for anti-influenza virus drugs--chemotherapy for influenza].
Shigeta, S, 1997
)
0.3
" Bioavailability of AMA and RIM was 34."( Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies.
Fujii, Y; Higashi, Y; Uemori, I, 2005
)
0.59
" The pharmacokinetic parameters and bioavailability of TZV were calculated after the administration of TZV to rabbits."( Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
Charushin, V; Chupakhin, O; Deev, S; Deeva, E; Ivanov, A; Karpenko, I; Kiselev, O; Kochetkov, S; Kukhanova, M; Rusinov, V; Smirnova, O; Ulomsky, E; Yanvarev, D, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The main objective was to modify therapy with adamantane derivatives: amantadine and rimantadine, to increase their bioavailability and evaluate the influence of such therapy on drug metabolism using Saccharomyces cerevisiae as the model organism."( Metabolic profiling to evaluate the impact of amantadine and rimantadine on the secondary metabolism of a model organism.
Barchanska, H; Kostina-Bednarz, M; Płonka, J, 2023
)
1.37

Dosage Studied

The efficacy of rimantadine in reducing the risk of clinical influenza-like illness was estimated to be 58 percent. At 300-mg/day dosage amantadne was associated more often with adverse central nervous system symptoms.

ExcerptRelevanceReference
" This allowed a total dosage not much less than might have been given by other routes, but with the advantage that it was evenly deposited over the surface of the infected respiratory tract beginning within seconds of the start of treatment and reached higher concentration in nasal secretions than in serum."( Chemotherapy of respiratory viruses.
Gilbert, BE; Knight, V, 1986
)
0.27
" These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms."( Antiviral chemotherapy and chemoprophylaxis.
Dolin, R, 1985
)
0.27
" These findings suggest that rimantadine dosage may need to be reduced in patients with end-stage renal disease but supplemental doses on dialysis days are not required."( Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure.
Capparelli, EV; Chow, MS; Izard, M; Stevens, RC; Wills, RJ, 1988
)
2.01
" A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms."( Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
, 1985
)
0.55
" Administration of 50 mg of the drug for 15-30 days was effective for prevention of influenza, and administration, early in the course of illness, of dosage of 150 mg per day for three to five days resulted in a favorable clinical response."( Study of rimantadine in the USSR: a review of the literature.
Kamforin, LE; Kovaleva, TP; Kubar, OI; Zlydnikov, DM,
)
0.55
"To provide a review of rimantadine, including its antiviral activity, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage and administration."( Rimantadine: a clinical perspective.
Nahata, MC; Wintermeyer, SM, 1995
)
2.04
" Careful attention to published dosage adjustment guidelines for these compounds, avoidance of interacting drugs and avoiding these agents in patients with a history of seizures may be the best means to reduce the risk of toxicity in elderly patients."( Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.
Guay, DR, 1994
)
0.64
" Adverse effects are more prominent in the elderly but can be minimized by dosage reductions."( Use of antivirals in influenza in the elderly: prophylaxis and therapy.
Nicholson, KG, 1996
)
0.29
" Because no prospective data exist on the efficacy of these agents in humans for H5N1 strains, the dosage and duration of therapy in adults and children may differ from those documented to be effective for epidemic influenza strains."( Antiviral therapy and prophylaxis for influenza in children.
, 2007
)
0.34
" Dosing of oseltamivir was variable, illustrating the need for pharmacokinetic data in this younger population."( Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.
Abughali, N; Abzug, MJ; Bradley, JS; Cloud, GA; Englund, J; Griffin, J; Guzman-Cottrill, J; Jacobs, RF; Jester, P; Kimberlin, DW; Lang, D; Leach, C; Ramilo, O; Robinson, J; Romero, JR; Shalabi, M; Shelton, M; Storch, G; Wade, KC; Whitley, RJ, 2010
)
0.36
" At higher dosage (0."( Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice.
Galabov, AS; Gegova, G; Simeonova, L, 2012
)
0.63
" Based on the significant quenching of the supramolecular complex fluorescence intensity, a fluorescent probe method of high sensitivity and selectivity was developed to determine AMA or RIM in their pharmaceutical dosage forms and in urine samples with good precision and accuracy."( Determination of amantadine and rimantadine using a sensitive fluorescent probe.
Chang, YX; Du, LM; Jing, X; Li, JF; Qin, YF; Wang, GQ; Wu, H, 2012
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylamineAny primary amine in which the substituent attached to nitrogen is an alkyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency0.01180.001310.157742.8575AID1259252
DNA polymerase kappa isoform 1Homo sapiens (human)Potency23.77810.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)4.40000.40003.10009.7000AID721751
Polymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)11.00001.88004.68805.8600AID1532117
Matrix protein 2Influenza A virus (A/udorn/1972(H3N2))IC50 (µMol)255.40004.70004.70004.7000AID1056008; AID1056009; AID1409732; AID729295
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)288.00000.16003.95718.6000AID721752
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)7.30000.01002.765610.0000AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Matrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))Kd0.01600.01600.89872.3600AID489224
Matrix protein 2Influenza A virus (A/udorn/1972(H3N2))Kd3,335.83670.51004.67009.0000AID1409720; AID1409737; AID1409745
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
uncoating of virusMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
proton transmembrane transporter activityMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
extracellular regionPolymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
extracellular regionMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (398)

Assay IDTitleYearJournalArticle
AID1589057Selectivity index, ratio of CC50 for cytotoxicity in MDCK cells to IC50 for antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
5-Chloro-2-thiophenyl-1,2,3-triazolylmethyldihydroquinolines as dual inhibitors of Mycobacterium tuberculosis and influenza virus: Synthesis and evaluation.
AID1456573Cytotoxicity against MDCK cells assessed as cell death by MTT assay2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Synthesis of camphecene derivatives using click chemistry methodology and study of their antiviral activity.
AID1482889Antiviral activity against Influenza A virus A//HK/7/87 (H3N2) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in plaque formation preincubated with virus for 1 hr followed by addition to cells measured after 72 hrs by 2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID536242Antiparasitic activity against Trypanosoma brucei 427 bloodstream forms assessed as inhibition of parasite growth after 48 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID1662711Cytotoxicity against MDCK cells2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Synthesis and biological evaluation of 6-nitro-1,2,4-triazoloazines containing polyphenol fragments possessing antioxidant and antiviral activity.
AID1877503Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells infected with Influenza A virus A/Puerto Rico/8/34 (H1N1) to IC50 for antiviral activity against Influenza A virus A/Puerto Rico/8/34 (H1N1) infected in MDCK cells2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses.
AID1485245Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1409723Antiviral activity against Influenza A virus A/Udorn/72 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1181485Cytotoxicity against MDCK cells assessed as change in cell morphology after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID712810Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1113452Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID416779Cytotoxicity against MDCK cells by MTS assay2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID712808Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID700858Half life in human plasma2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1456575Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Synthesis of camphecene derivatives using click chemistry methodology and study of their antiviral activity.
AID712811Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID658750Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID388539Antiviral activity against influenza virus B/Hong Kong/5/72 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID766694Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID539957Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1152167Cytotoxicity against MDCK cells at 50 uM after 18 hrs2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID548444Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID105953Antiviral activity against influenza A virus (Mississippi) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID1409740Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 2 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1532118Cytotoxicity against MDCK cells after 24 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Non-chelating p-phenylidene-linked bis-imidazoline analogs of known influenza virus endonuclease inhibitors: Synthesis and anti-influenza activity.
AID1056009Inhibition of Influenza A virus M2 ion channel V27A mutant by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID523869Apparent elimination half life in rabbit at 4.3 mg/kg, iv by HPLC analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID416782Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID539958Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1360698Cytotoxicity against MDCK cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1498139Cytotoxicity against MDCK cells assessed as alteration of cell morphology by microscopic analysis2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID105955Antiviral activity against influenza A virus (NY/83/R6) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1485251Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1194477Antiviral activity against influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as decrease in virus titer by hemagglutination assay in presence of 1% suspension of chicken erythrocytes2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors.
AID712796Cytotoxicity against dog MDCK cells assessed as cell morphology alterations2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID416383Antitrypanosomal activity against Trypanosoma brucei 427 assessed as parasite growth inhibition after 48 hrs2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
AID1055983Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1532119Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) PA endonuclease infected in MDCK cells2019European journal of medicinal chemistry, Jan-01, Volume: 161Non-chelating p-phenylidene-linked bis-imidazoline analogs of known influenza virus endonuclease inhibitors: Synthesis and anti-influenza activity.
AID523847Antiviral activity against Influenza A virus (A/Hong Kong/1073/99(H9N2)) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID717281Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1321606Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in chicken erythrocytes incubated for 1 hr with supernatants from 1 hr compound pre-treated MDCK cells infected with Influenza A virus (A/California/07/2009(H1N1)) pdm02016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Anti-influenza activity of monoterpene-derived substituted hexahydro-2H-chromenes.
AID1360699Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID683699Antimalarial activity against liver stages of Plasmodium yoelii yoelii2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID443829Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID548441Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1485244Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID523683Antiviral activity against Influenza A virus (A/Vietnam/1194/2004 (H5N1)) infected in MDCK cells assessed as log reduction in viral titer at 502 uM after 48 hrs by MTT assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID548442Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1571468Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Synthesis of d-(+)-camphor-based
AID1456574Antiviral activity against rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Synthesis of camphecene derivatives using click chemistry methodology and study of their antiviral activity.
AID539955Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID766686Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1055982Cytotoxicity against MDCK cells after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID751947Therapeutic index, ratio of CC50 for dog MDCK cells to EC50 for 100 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N22013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID712795Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID718709Selectivity index, ratio of CTD50 for MDCK cells to ED50 for influenza virus A/California/07/09 (H1N1) pdm092012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
AID1485246Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1415636Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and
AID717280Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID105957Antiviral activity against influenza B virus (Ann Arbor) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID1877502Cytotoxicity against MDCK cells infected with Influenza A virus A/Puerto Rico/8/34 (H1N1) assessed as reduction in cell viability2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses.
AID1877501Antiviral activity against Influenza A virus A/Puerto Rico/8/34 (H1N1) infected in MDCK cells assessed as inhibition of viral replication2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses.
AID766685Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1321608Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/California/07/09(H1N1)) pdm092016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Anti-influenza activity of monoterpene-derived substituted hexahydro-2H-chromenes.
AID1498140Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1408322Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1055980Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 2 log10 reduction of virus yield after 24 hrs by RT-PCR analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1181483Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1408325Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID443838Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as cell viability at subtoxic concentration by cell-based MTS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1409744Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as dissociation constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID536241Cytotoxicity against MDCK cells by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID1113454Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1467226Cytotoxicity against MDCK cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Anti-influenza activity of monoterpene-containing substituted coumarins.
AID1055988Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID461005Cytotoxicity against MDCK cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus.
AID751949Cytotoxicity against dog MDCK cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID523849Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) infected in rabbit assessed as survival rate at 100 mg/kg, ig administered 1 and 24 hrs before infection and 24 to 72 hrs post infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1408332Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1409725Antiviral activity against Influenza A virus A/WSN/33 H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID768187Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1152164Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID606801Antitrypanosomal activity against Trypanosoma brucei2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Novel lipophilic acetohydroxamic acid derivatives based on conformationally constrained spiro carbocyclic 2,6-diketopiperazine scaffolds with potent trypanocidal activity.
AID718711Cytotoxicity against MDCK cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
AID1485247Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1571470Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells2018MedChemComm, Dec-01, Volume: 9, Issue:12
Synthesis of d-(+)-camphor-based
AID523873Total clearance in rabbit at 4.3 mg/kg, iv up to 24 hrs by HPLC analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1152162Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID658749Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID308660Antiparasitic activity against Trypanosoma brucei 221 blood stream form at pH 7.42007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID1408328Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1699936Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
AID1202567Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as virus plaque reduction preincubated for 1 hr followed by compound wash out and incubated for 72 hrs by crystal violet staining2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409733Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at pH 5.5 after 5 mins by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1202565Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID478324Antiviral activity against influenza B virus assessed as inhibition of viral induced cytopathic effect2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID718741Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID456470Trypanocidal activity against Trypanosoma brucei 427 bloodstream form assessed as decrease in cell density after 48 hrs by hemocytometry2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID1409741Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 5 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID388540Cytotoxicity against MDCK cells by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1409743Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as association constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID658746Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1409727Antiviral activity against Influenza A virus A/Udorn/72 H3N2 infected in MDCK cells assessed as reduction in plaque formation by crystal violet staining based assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID548437Cytotoxicity against MDCK cells assessed as cell viability by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1298244Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID658747Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1610159Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID388527Antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1495714Antiviral activity against amantadine/rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Highly potent activity of isopulegol-derived substituted octahydro-2H-chromen-4-ols against influenza A and B viruses.
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1589054Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus titer using cells pre-treated with compound followed by virus infection for 24 hrs by hemagglutination test2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
5-Chloro-2-thiophenyl-1,2,3-triazolylmethyldihydroquinolines as dual inhibitors of Mycobacterium tuberculosis and influenza virus: Synthesis and evaluation.
AID658607Cytotoxicity against MDCK cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1610155Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID712814Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID523692Antiviral activity against Influenza A virus (A/Hong Kong/1073/99(H9N2)) infected in MDCK cells assessed as log reduction in viral titer at 502 uM after 48 hrs by MTT assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID416785Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID387576Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID523843Antiviral activity against Influenza A virus H7N3 (A/Mallard/NT/12/02) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1056008Inhibition of Influenza A virus M2 ion channel S31N mutant by two-electrode voltage clamp assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID105793Antiviral activity of compound was tested against morphology virus infec+ted MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID523689Antiviral activity against Influenza A virus/H7N3 (A/Mallard/NT/12/02) infected in MDCK cells assessed as log reduction in viral titer at 502 uM after 48 hrs by MTT assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1360697Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID729294Inhibition of Influenza A virus wild type M2 proton channel expressed in Xenopus laevis oocyte after 2 mins by two-electrode patch clamp assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1409724Antiviral activity against Influenza A virus A/WSN/33 H1N1 harboring N31S mutant infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1201115Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1610162Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1610157Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID523686Antiviral activity against Influenza A virus (A/duck/Potsdam/1402-6/1986 (H5N2)) infected in MDCK cells assessed as log reduction in viral titer at 502 uM after 48 hrs by MTT assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1152165Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1194478Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors.
AID717174Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1409730Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 5 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID536243Selectivity index, ratio of MCC for MDCK cells to EC50 for Influenza A virus (A/Hong Kong/7/1987(H3N2))2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID443837Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as inhibition of virus-induced cytopathic effect at highest concentration by cell-based assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID478321Antiviral activity against influenza A virus H1N1 assessed as cell viability by cell based MTS assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID105792Antiviral activity against influenza B virus infected MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID416778Cytotoxicity against MDCK cells assessed as drug level causing microscopically detectable alteration of normal cell morphology2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID717172Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1415635Cytotoxicity against MDCK cells after 48 hrs by MTT assay2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1408329Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1181478Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID717170Cytotoxicity against dog MDCK cells assessed as cell morphology alterations by microscopic analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1498125Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID712816Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID308657Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID1202563Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID523705Antiviral activity against Influenza A virus H0N1 (A/PR/8/34) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1616108Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID1610156Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID105954Antiviral activity against influenza A virus (NY/83/5) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID523709Antiviral activity against Influenza A virus (A/Vietnam/1194/2004 (H5N1)) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID523697Antiviral activity against Influenza B virus (B/Samara/253/99) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1682703Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay
AID1877504Antiviral activity against Influenza A virus A/Anhui/1/2013 (H7N9) infected in MDCK cells assessed as inhibition of viral replication2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses.
AID461007Selectivity index, ratio of CTD50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus.
AID478322Antiviral activity against Influenza A virus H3N2 assessed as inhibition of viral induced cytopathic effect2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID751952Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2))-infected in Balb/c mouse at 2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID712809Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1662712Selectivity index, ratio of CC50 for MDCK cells to IC50 for M2 proton channel in Influenza A virus (A/Puerto Rico/8/34(H1N1) ) infected in MDCK cells assessed as inhibition of viral infection2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Synthesis and biological evaluation of 6-nitro-1,2,4-triazoloazines containing polyphenol fragments possessing antioxidant and antiviral activity.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID416784Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1571469Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in virus titer pretreated with cells for 1 hr followed by viral infection for 1 hr and subsequent unbound virion washout measured after 242018MedChemComm, Dec-01, Volume: 9, Issue:12
Synthesis of d-(+)-camphor-based
AID718739Toxicity in MDCK cells assessed as induction of cell morphology changes2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID1485249Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID105787Antiviral activity tested against influenza A,H1N1 virus infected MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1610158Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID523850Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) infected in rabbit assessed as survival rate at 50 mg/kg, ig administered 1 and 24 hrs before infection and 24 to 72 hrs post infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1589055Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
5-Chloro-2-thiophenyl-1,2,3-triazolylmethyldihydroquinolines as dual inhibitors of Mycobacterium tuberculosis and influenza virus: Synthesis and evaluation.
AID523853Antiviral activity against Influenza B virus (B/Lee/1940) infected in rabbit assessed as survival rate at 50 mg/kg, ig administered 1 and 24 hrs before infection and 24 to 72 hrs post infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1201117Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID712807Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID768189Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID387575Cytotoxicity against MDCK cells assessed as alteration in cell morphology by MTS assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID768188Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID523680Antiviral activity against Influenza A virus H3N2 (A/Victoria/35/72) infected in MDCK cells assessed as log reduction in viral titer at 502 uM after 48 hrs by MTT assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID523701Antiviral activity against Influenza A virus H3N2 (A/Victoria/35/72) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID658748Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1532117Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) PA endonuclease infected in MDCK cells assessed as reduction in virus titer treated with cells for 1 hr prior to viral infection for 1 hr followed by compound washout and subsequent compound addit2019European journal of medicinal chemistry, Jan-01, Volume: 161Non-chelating p-phenylidene-linked bis-imidazoline analogs of known influenza virus endonuclease inhibitors: Synthesis and anti-influenza activity.
AID718710Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
AID1202566Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID1408323Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID658751Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1152166Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1498123Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1181482Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID478320Antiviral activity against influenza A virus H1N1 assessed as inhibition of viral induced cytopathic effect2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID393164Cytotoxicity against MDCK cells assessed as changes in cell morphology after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID1181481Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1408326Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1055984Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID751951Antiviral activity against 1 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2) infected in dog MDCK cells assessed as virus-induced cytopathic effect after 48 hrs2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID393166Antiviral activity against influenza B virus2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID658606Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID717171Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID416780Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1409726Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID751950Antiviral activity against 100 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2) infected in dog MDCK cells assessed as virus-induced cytopathic effect after 48 hrs2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID1194479Selectivity index, CTD50 for MDCK cells to EC50 for influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors.
AID1055999Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by microsocopic analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID768212Cytotoxicity against MDCK cells assessed as cell viability after 4 days by MTS assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID308659Selectivity index, ratio of EC50 for influenza A/Hong Kong/7/87 (H3N2) to MCC for MDCK cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID717169Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1055986Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 1 log10 reduction of virus yield after 24 hrs by RT-PCR analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1616107Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID1611059Cytotoxicity against dog MDCK cells assessed as cell death incubated for 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID1409736Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as dissociation constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1409721Binding affinity to Influenza A virus A/Udorn/72 M2 proton channel S31N mutant by isothermal calorimetric titration2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1877506Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells infected with Influenza A virus A/Anhui/1/2013 (H7N9) to IC50 for antiviral activity against Influenza A virus A/Anhui/1/2013 (H7N9) infected in MDCK cells2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses.
AID1877505Cytotoxicity against MDCK cells infected with Influenza A virus A/Anhui/1/2013 (H7N9) assessed as reduction in cell viability2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1699935Antiviral activity against Influenza A virus (A/California/07/09(H1N1))pdm09 infected in MDCK cells assessed as reduction in viral replication preincubated with compound for 1 hr followed by viral infection and measured after viral cultivation for 48 hrs 2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
AID478323Antiviral activity against Influenza A virus H3N2 assessed as cell viability by cell based MTS assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID523875Volume of distribution at steady state in rabbit at 4.3 mg/kg, iv up to 24 hrs by HPLC analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1113455Cytotoxicity against MDCK cells assessed as change in cellular morphology2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1415634Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in viral titer preincubated with cells for 1 hr followed by viral inoculation and measured after 48 hrs by hemagglutination test2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and
AID1611060Selectivity index, ratio of CTD50 for dog MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) pdm09 infected in MDCK cells2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID1298254Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID105964Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H3N2 (X31)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID461006Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as virus yield after 48 hrs end-point dilution method2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus.
AID1360696Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1202564Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID416783Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID388523Trypanocidal activity against Trypanosoma brucei 427 blood stream after 48 hrs by hemocytometer2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1409729Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 2 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1485248Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID443828Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as cell viability by cell-based MTS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1662710Inhibition of M2 proton channel in Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral infection2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Synthesis and biological evaluation of 6-nitro-1,2,4-triazoloazines containing polyphenol fragments possessing antioxidant and antiviral activity.
AID1610161Cytotoxicity against dog MDCK cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1409737Binding affinity to Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1682702Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in MDCK cells
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID308658Cytotoxicity against MDCK cells assessed as changes in cell morphology2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Design and synthesis of bioactive adamantane spiro heterocycles.
AID1467225Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells pretreated for 1 hr followed by viral infection incubated for 24 hrs measured after 48 hrs by hemagglutination test2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Anti-influenza activity of monoterpene-containing substituted coumarins.
AID523852Antiviral activity against Influenza B virus (B/Lee/1940) infected in rabbit assessed as survival rate at 100 mg/kg, ig administered 1 and 24 hrs before infection and 24 to 72 hrs post infection2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID105790Antiviral activity against influenza A,H3N2 virus infected MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID729295Inhibition of Influenza A virus M2 proton channel S31N mutant expressed in Xenopus laevis oocyte after 2 mins by two-electrode patch clamp assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.
AID1498141Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID548439Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID637741Antitrypanosomal activity against bloodstream form of Trypanosoma brucei 427 after 48 hrs by hemocytometer analysis2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.
AID478325Antiviral activity against influenza B virus assessed as cell viability by cell based MTS assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID1409745Binding affinity to Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1321607Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Anti-influenza activity of monoterpene-derived substituted hexahydro-2H-chromenes.
AID1201119Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1409720Binding affinity to Influenza A virus A/Udorn/72 wild-type M2 proton channel by isothermal calorimetric titration2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID539948Cytotoxicity against MDCK cells by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1482890Antiviral activity against Influenza A virus A//HK/7/87 (H3N2) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in viral yield after 24 hrs by RT-qPCR method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID1409735Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as association constant at pH 5.5 by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID717173Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1201121Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1055981Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID105788Antiviral activity against influenza A,H2N2 virus infected MDCK cell lines.1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1409722Antiviral activity against Influenza A virus (A/Hong Kong/68(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID766706Cytotoxicity against MDCK cells assessed as morphological changes2013European journal of medicinal chemistry, Sep, Volume: 67Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID751953Acute toxicity in sc dosed Balb/c mouse after 5 days2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID1201116Cytotoxicity against MDCK cells after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID393165Selectivity index, ratio of MCC for MDCK cells to EC50 for influenza A virus H3N22009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID523839Antiviral activity against Influenza A virus (A/duck/Potsdam/1402-6/1986 (H5N2)) infection in chick chorioallantoic membrane assessed as log reduction in viral titer at 110 uM after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1181479Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1201122Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID548440Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1498142Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1152163Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1201118Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1113453Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1408324Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID443827Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1482891Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
AID1055979Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 24 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1409731Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 10 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID523871Mean residence time in rabbit at 4.3 mg/kg, iv by HPLC analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1467227Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Anti-influenza activity of monoterpene-containing substituted coumarins.
AID751948Therapeutic index, ratio of CC50 for dog MDCK cells to EC50 for 1 infective dose of influenza A virus A/St. Petersburg/34/72 (H3N2)2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Anti-influenza active and low toxic N-phenyl-substituted β-amidoamidines structurally related to natural antibiotic amidinomycin.
AID548443Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID388538Antiviral activity against influenza virus A/Hong Kong/7/87 H3N2 in MDCK cells assessed as effect on virus-induced cytopathogenicity by MTS assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID539949Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1610160Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1682704Antiviral activity against Influenza A virus (A/Puerto Rico/8/34 (H1N1) infected in MDCK cells assessed as decrease in viral titer preincubated for 1 hr followed by viral infection and cultivated for 48 hrs followed by supernatant transferred to chicken e
AID1201120Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID105973Concentration required to reduce the viability of MDCK cells1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID1409732Inhibition of Influenza A virus A/Udorn/72 wild-type M2 proton channel expressed in Xenopus laevis oocytes assessed as blockade of inward currents at pH 5.5 after 2 mins by two-electrode voltage clamp assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1408327Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells after 3 days by MTS assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1498124Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1699937Selectivity index, ratio of CC50 for dog MDCK cells to IC50 for Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
AID1495715Selectivity index, ratio of CC50 for MDCK cells to IC50 for amantadine/rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1))2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Highly potent activity of isopulegol-derived substituted octahydro-2H-chromen-4-ols against influenza A and B viruses.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID718742Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID539953Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1495713Cytotoxicity against MDCK cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Highly potent activity of isopulegol-derived substituted octahydro-2H-chromen-4-ols against influenza A and B viruses.
AID1181480Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1055987Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) harboring M2 channel S31N and V27T mutant infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID536238Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID548438Cytotoxicity against MDCK cells assessed as altered cell morphology2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID712812Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID416781Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID393162Antiviral activity against influenza A virus H3N2 assessed as inhibition of virus-induced cytopathic effect after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID1485250Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID105956Antiviral activity against influenza A virus (Taiwan) in Madin Darby canine kidney (MDCK) cell culture1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiviral activity of metabolites of rimantadine.
AID539956Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID489224Binding affinity to Influenza A Weybridge(H7N7) virus Matrix protein 2 by spectrophotometry2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model.
AID1298255Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID443830Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as cell viability by cell-based MTS assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1409742Inhibition of Influenza A virus A/Udorn/72 M2 proton channel S31N mutant expressed in Xenopus laevis oocytes assessed as blockade of inward currents at 100 uM at pH 5.5 after 10 mins by two-electrode voltage clamp assay relative to control2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.
AID1181494Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID523867Total AUC in rabbit at 4.3 mg/kg, iv up to 24 hrs by HPLC analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
AID1611058Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of virus replication compound incubated with uninfected host cell for 1 hr followed by viral infection for 24 hrs measured after vi2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID1202568Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in MDCK cells assessed as 2-log10 reduction in virus yield after 24 hrs by RT-qPCR analysis2015European journal of medicinal chemistry, , Volume: 96New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode.
AID105965Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza B (Hong Kong/5/72)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID718740Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID1408333Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 3 days by microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1181493Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1181484Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID105963Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H2N2 strain (A2 Japan/305/57)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID539954Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1055985Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as reduction of cytopathic effect after 72 hrs by MTS assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (538)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990131 (24.35)18.7374
1990's108 (20.07)18.2507
2000's137 (25.46)29.6817
2010's133 (24.72)24.3611
2020's29 (5.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.10 (24.57)
Research Supply Index6.55 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index86.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (7.22%)5.53%
Reviews100 (15.36%)6.00%
Case Studies5 (0.77%)4.05%
Observational0 (0.00%)0.25%
Other499 (76.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Os [NCT01172847]Phase 124 participants (Actual)Interventional2009-08-31Completed
A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin [NCT01413490]10 participants (Actual)Observational2012-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01172847 (8) [back to overview]Maximum Plasma Concentration (Cmax) of Rimantadine
NCT01172847 (8) [back to overview]Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)
NCT01172847 (8) [back to overview]Number of Participants With Clinically Significant or Treatment Related Changes in Electrocardiogram (ECG)
NCT01172847 (8) [back to overview]Steady State Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours After Dosing (AUC0-12) of Rimantadine
NCT01172847 (8) [back to overview]Maximum Plasma Concentration (Cmax) of Oseltamivir and Oseltamivir Carboxylate
NCT01172847 (8) [back to overview]Number of Participants With Abnormal Vital Signs
NCT01172847 (8) [back to overview]Number of Participants With Marked Abnormality in Laboratory Parameters
NCT01172847 (8) [back to overview]Steady State Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours After Dosing (AUC0-12) of Oseltamivir and Oseltamivir Carboxylate

Maximum Plasma Concentration (Cmax) of Rimantadine

Cmax of rimantadine was calculated following the administration of rimantadine alone or in combination with oseltamivir and was directly observed from the data. (NCT01172847)
Timeframe: Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose on Day 5

Interventionng/mL (Least Squares Mean)
Oseltamivir6.036
Oseltamivir + Rimantadine6.062

[back to top]

Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect. (NCT01172847)
Timeframe: Up to 11 weeks

Interventionparticipants (Number)
Oseltamivir8
Rimantadine6
Oseltamivir + Rimantadine4

[back to top] [back to top]

Steady State Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours After Dosing (AUC0-12) of Rimantadine

AUC0-12 of rimantadine was calculated following the administration of rimantadine alone or in combination with oseltamivir, using the linear trapezoidal rule. (NCT01172847)
Timeframe: Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose on Day 5

Interventionh*ng/mL (Least Squares Mean)
Rimantadine8.371
Oseltamivir + Rimantadine8.398

[back to top]

Maximum Plasma Concentration (Cmax) of Oseltamivir and Oseltamivir Carboxylate

Oseltamivir carboxylate is active metabolite of oseltamivir. Cmax of oseltamivir and oseltamivir carboxylate were calculated following the administration of oseltamivir alone or in combination with rimantadine and was directly observed from the data. (NCT01172847)
Timeframe: Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose on Day 5

,
Interventionng/mL (Least Squares Mean)
OseltamivirOseltamivir Carboxylate
Oseltamivir4.3955.940
Oseltamivir + Rimantadine4.2495.921

[back to top]

Number of Participants With Abnormal Vital Signs

Vital signs included heart rate (HR), blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), and body temperature. Blood pressure and pulse rate were recorded when participants were rested in a supine position for at least 5 minutes and after standing for 2 minutes. Vital signs values that fall outside the investigator's normal ranges were recorded. (NCT01172847)
Timeframe: Screening (Days -28 to -2); pre-dose and 2h post-dose on D1 and D5 of each treatment period; at Follow-up visit (10 -14 days after last dose) for blood pressure and HR; Screening; Day -1 of each treatment period; Follow-up visit for temperature

,,
Interventionparticipants (Number)
High- SBPHigh- DBPHigh- DBP standingHigh- SBP standingHigh- HRHigh- HR standingLow- Temperature
Oseltamivir6287227
Oseltamivir + Rimantadine2023028
Rimantadine10640111

[back to top]

Number of Participants With Marked Abnormality in Laboratory Parameters

"Laboratory analysis included hematology (hemoglobin, hematocrit, erythrocytes, platelets counts, leukocytes counts, neutrophils, eosinophils, lymphocytes, basophils, and monocytes);, biochemistry (aspartate aminotransferase , alanine aminotransferase, gamma glutamyl trans peptidase, total bilirubin, alkaline phosphatase, lactate dehydrogenase, albumin, creatinine, urea, creatine phosphokinase, total protein, sodium, chloride, calcium, phosphate, potassium, glucose (fasting), amylase, lipase, total cholesterol, and calculated creatinine clearance); and urinalysis.~Marked laboratory test values (high and low) falling outside the marked reference range and which also represents a clinically relevant change from baseline of at least a designated amount were recoded. In this study, marked abnormality ranges for phosphate as 0.75 - 1.60 millimole (mmol)/L and proteinuria (0 to 4+, and 1)." (NCT01172847)
Timeframe: Screening; Day -1 and Day 5 (pre-dose) of each treatment period; Follow-up visit

,,
Interventionparticipants (Number)
Phosphate HighPhosphate LowProteinuria
Oseltamivir111
Oseltamivir + Rimantadine100
Rimantadine100

[back to top]

Steady State Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours After Dosing (AUC0-12) of Oseltamivir and Oseltamivir Carboxylate

Oseltamivir carboxylate is active metabolite of oseltamivir. AUC0-12 of oseltamivir and oseltamivir carboxylate were calculated following the administration of oseltamivir alone or in combination with rimantadine, using the linear trapezoidal rule. (NCT01172847)
Timeframe: Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose on Day 5

,
Interventionhours (h)*nanogram (ng)/milliliter (mL) (Least Squares Mean)
OseltamivirOseltamivir Carboxylate
Oseltamivir5.0928.008
Oseltamivir + Rimantadine5.0707.990

[back to top]